296 related articles for article (PubMed ID: 18507034)
1. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
Tencer L; Burgermeister E; Ebert MP; Liscovitch M
Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
[TBL] [Abstract][Full Text] [Related]
2. 15-deoxy-Delta12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells.
Chen ZY; Tseng CC
Mol Pharmacol; 2005 Nov; 68(5):1203-13. PubMed ID: 16077033
[TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
5. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
6. Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme.
Varley CL; Stahlschmidt J; Lee WC; Holder J; Diggle C; Selby PJ; Trejdosiewicz LK; Southgate J
J Cell Sci; 2004 Apr; 117(Pt 10):2029-36. PubMed ID: 15054105
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 inhibits the growth of human laryngeal squamous cell carcinoma and down regulates EGFR-MAPKs signaling pathway.
Gu D; Li H; Wang Z; Chen Q; Jiang J; Zhu H
Laryngoscope; 2007 Oct; 117(10):1782-9. PubMed ID: 17906498
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.
Kim KY; Ahn JH; Cheon HG
Mol Pharmacol; 2007 Sep; 72(3):674-85. PubMed ID: 17535976
[TBL] [Abstract][Full Text] [Related]
9. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor in cultured human retinal pigment epithelial cells.
Yan F; Hui YN; Li YJ; Guo CM; Meng H
Ophthalmologica; 2007; 221(4):244-50. PubMed ID: 17579290
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma regulates expression of signal transducer and activator of transcription 5A.
Olsen H; Haldosén LA
Exp Cell Res; 2006 May; 312(8):1371-80. PubMed ID: 16457814
[TBL] [Abstract][Full Text] [Related]
12. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR.
Chen A; Xu J
Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G447-56. PubMed ID: 15486348
[TBL] [Abstract][Full Text] [Related]
13. Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPARgamma in A549 cells.
Kim HJ; Woo IS; Kang ES; Eun SY; Kim GH; Ham SA; Kim HJ; Lee JH; Chang KC; Kim JH; Lee HT; Seo HG
Biochem Biophys Res Commun; 2006 Oct; 349(2):660-7. PubMed ID: 16945329
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
16. Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration.
Ravid D; Chuderland D; Landsman L; Lavie Y; Reich R; Liscovitch M
Exp Cell Res; 2008 Sep; 314(15):2762-73. PubMed ID: 18598695
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
[TBL] [Abstract][Full Text] [Related]
18. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Achanzar WE; Moyer CF; Marthaler LT; Gullo R; Chen SJ; French MH; Watson LM; Rhodes JW; Kozlosky JC; White MR; Foster WR; Burgun JJ; Car BD; Cosma GN; Dominick MA
Toxicol Appl Pharmacol; 2007 Sep; 223(3):246-56. PubMed ID: 17663016
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma.
Li X; Yang X; Xu Y; Jiang X; Li X; Nan F; Tang H
Cell Res; 2009 Jun; 19(6):720-32. PubMed ID: 19417774
[TBL] [Abstract][Full Text] [Related]
20. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
